STK-012 drug for advanced lung cancer and other tumors
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests STK-012 (alone and with other treatments) in people with advanced cancers, especially non-small cell lung cancer. It may help by activating the immune system to recognize and fight the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced solid tumors; for the lung-cancer part, it’s non-small cell lung cancer (NSCLC).
- If it’s lung cancer, it must be stage IV or stage IIIB/IIIC and not eligible for curative (definitive) treatment.
- Your lung tumor must be non-squamous cell type, and you have not had chemo or other body-wide treatment for advanced lung cancer yet.
- Your tumor must match at least one marker: PD-L1 is negative (TPS under 1%), or your tumor has STK11 mutation (in tumor tissue or blood/ctDNA).
- You should not have common gene changes that already have a standard first-line targeted treatment (like EGFR, ALK, ROS1, or other actionable changes).
- For the lung-cancer part: you cannot have had an immune checkpoint inhibitor before, recent radiation (within 7 days), or active brain metastases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental drug called STX-1, given alone or with another drug that helps the immune system fight cancer. It is for people with advanced solid tumors, especially certain types of lung cancer or melanoma, who have already tried standard treatments.
This trial tests a new drug called STX-001, which is injected directly into a tumor to help the immune system fight cancer. It is being studied alone or with another immunotherapy (pembrolizumab) for people with advanced solid tumors, including melanoma or triple-negative breast cancer.
This trial tests a new study drug called PF-08634404 combined with standard chemotherapy for people with advanced lung cancer that has not been treated before. It aims to see if this combination works better than chemotherapy alone.
This trial tests whether a new drug combination (SYS6010 plus enlonstobart) works better than standard immunotherapy with chemotherapy for patients with advanced non-small cell lung cancer. You may qualify if you have not received prior cancer treatment and have a specific marker (PD-L1) on your tumor.
This Phase 1 trial studies how safe ASKC202 is, what dose is tolerable, and whether it shows early signs of shrinking certain advanced cancers. Depending on your tumor type and prior treatments, ASKC202 may be tested alone or with another drug.
This early-phase study tests STI-7349 (a new cancer treatment) in people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see how well it can control cancer.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.